UK markets open in 1 hour 1 minute

Zevra Therapeutics, Inc. (1GDA.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
4.7200-0.0200 (-0.42%)
At close: 08:00AM CEST
Full screen
Previous close4.7400
Open4.7200
Bid4.7000 x N/A
Ask4.7600 x N/A
Day's range4.7200 - 4.7200
52-week range3.8200 - 6.4500
Volume605
Avg. volume18
Market cap200.034M
Beta (5Y monthly)1.87
PE ratio (TTM)N/A
EPS (TTM)-1.2100
Earnings date08 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Insider Monkey

    Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript

    Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Q1 2024 Earnings Call Transcript May 8, 2024 Zevra Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, everyone. Thank you for joining the Zevra Therapeutics’ First Quarter 2024 Corporate Update and Financial […]

  • GlobeNewswire

    Zevra Therapeutics to Participate at Upcoming Investor Events

    CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane, President and Chief Executive Officer of Zevra, will present at several upcoming investor events in May 2024. Additionally, management will be available for one-on-one meetings with registered attendees. Mr. McFarlane will present at The Citizens JMP Life Sciences Conference in New York, NY, on Tuesday,

  • Simply Wall St.

    Zevra Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

    Zevra Therapeutics ( NASDAQ:ZVRA ) First Quarter 2024 Results Key Financial Results Revenue: US$3.43m (up 19% from 1Q...